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ABSTRACT 
 
Background: Chemotherapy is a well-established therapeutic modality known for 
ages for the treatment of breast cancer. Both adjuvant and neoadjuvant chemotherapy 
has significantly reduced the morbidity and mortality associated with breast cancer. 
However, chemotherapy is associated with an increased incidence of adverse effects 
attributed to the drug as well as patient characteristics.  
 In majority of patients, the dose which produces the therapeutic effect may also be 
responsible for toxic effects. Therefore, optimizing the drug dosage to reduce the 
exposure may have the therapeutic advantage of maximizing the efficacy of the drug 
while reducing the adverse effects.  
Aim: To study the influence of plasma concentration of Adriamycin, 
Cyclophosphamide and Paclitaxel on the liver and renal functions, tumour size 
reduction, receptor status (ER/PR) and adverse drug effects of patients with breast 
cancer. 
Methodology: This study was done in the Department of Pharmacology, PSG 
Institute of Medical Sciences and Research (PSG IMS&R), Coimbatore during the 
period of November 2016 to October 2017. A total of 30 patients with breast cancer 
on AC/T regimen (Adriamycin and Cyclophosphamide 4 cycles followed by 
Paclitaxel 4 cycles) were enrolled and were grouped into 3, with 10 patients for each 
drug under study. The data pertaining to the treatment of breast cancer such as tumour 
size, drug and dosage, Estrogen/Progesterone receptor (ER/PR) status, laboratory 
parameters including liver and renal function test and complete blood count (CBC), 
nature of chemotherapy (adjuvant /neoadjuvant) and number of cycles completed were 
obtained from the medical records of the patient. Patients were also asked about the 
occurrence of adverse effects like nausea, vomiting, etc. 
About two ml of venous blood was collected from the study participants at the end of 
infusion of the drug and centrifuged to separate plasma. The samples were then 
analyzed using HPLC and the plasma concentration of the drugs was determined. 
Results: The mean plasma concentration of Adriamycin, Cyclophosphamide and 
Paclitaxel was found to be 3460.50, 1592.44 and 3038.29  ng/ml respectively. we 
found that the plasma concentration of the drugs showed inter-individual variations 
which were consistent with the previous studies. The statistical analysis was done 
using Pearson correlation. No significant correlation of plasma concentration of these 
chemotherapeutic drugs was found with the other clinical, biochemical and hormonal 
parameters. 
Conclusion: From our study we conclude that the plasma concentration alone is not a 
determinant of clinical outcome or toxicities in these patients. Dose optimisation has 
to be validated prospectively in a large group of patients with more pharmacokinetic-
pharmacodynamic parameters. 
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